Lance Milken, CEC’s chairman and partner at private-equity firm Apollo Global Management LLC, (NYSE:APO) in a statement commended Leverton’s “experience in the entertainment and restaurant industries, demonstrated success growing businesses and strong track record as a seasoned leader.”  New York-based Apollo Global Management took CEC private in a $1.3 billion deal in February. Apollo Global Management LLC (NYSE:APO) stock performance was 1.84% in last session and finished the day at $27.62. Traded volume was 1.04million shares in the last session and the average volume of the stock remained 1.43million shares. The beta of the stock remained 2.18. Apollo Global Management LLC (NYSE:APO) insider ownership is 3.50%.

QEP Resources, Inc. (NYSE:QEP) today announced that it will host a teleconference and webcast to discuss its second quarter 2014 results beginning at 9:00 a.m. EDT (7:00 a.m. MDT) on Thursday, August 7, 2014. QEP will issue a combined second quarter financial and operations press release Wednesday, August 6, 2014 after the market closes. QEP Resources Inc (NYSE:QEP) rose 2.41 percent to $34.45 Wednesday on volume of 1.78million shares. The intra-day range of the stock was $33.77 to $34.60. QEP Resources Inc (NYSE:QEP) has a market capitalization of $6.20billion.

Garrison Capital Inc. (NASDAQ:GARS) Announces Certain Preliminary Estimates for the Second Quarter Ended June 30, 2014 Garrison Capital Inc., a business development company (the “Company”) (NASDAQ:GARS), today announced certain preliminary estimates for the quarter ended June 30, 2014.  Garrison Capital Inc (NASDAQ:GARS)’s stock on July 16, 2014 reported a decrease of -1.93% to the closing price of $14.76. Its fifty two weeks range is $13.68 -$15.40. The total market capitalization recorded $247.36million. The overall volume in the last trading session was 47,734.00million shares. In its share capital, GARS has 16.76million outstanding shares.

Financial institutions traded 14 block trades on shares of Valeant Pharmaceuticals International Inc (NYSE:VRX). Further analysis into the trading activity revealed that 117,850 shares were bought and 143,250 shares were sold. The bought/sold ratio for shares of VRX is 0.82, representing a negative net cash flow of $3,117,436 out of the stock. On Wednesday, shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) advanced 1.89% to close the day at $121.71. Company return on investment (ROI) is -0.10% and its monthly performance is recorded as 3.36%. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) quarterly revenue growth is 1.32%.